Financials data is unavailable for this security.
View more
Year on year Sichuan Huiyu Pharmaceutical Co Ltd 's revenues fell -37.92% from 1.49bn to 927.08m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 248.99m to 139.79m, a -43.86% decrease.
| Gross margin | 83.61% |
|---|---|
| Net profit margin | 13.18% |
| Operating margin | 13.60% |
| Return on assets | 2.93% |
|---|---|
| Return on equity | 3.68% |
| Return on investment | 3.56% |
More ▼
Cash flow in CNYView more
In 2023, Sichuan Huiyu Pharmaceutical Co Ltd increased its cash reserves by 35.18%, or 424.22m. Cash Flow from Investing totalled 233.35m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 66.93m in cash from operations while cash generated from financing totalled 122.30m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 8.77 |
|---|---|
| Tangible book value per share | 8.56 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.93 |
|---|---|
| Quick ratio | 2.76 |
| Total debt/total equity | 0.1489 |
|---|---|
| Total debt/total capital | 0.1296 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -9.36% and -43.86%, respectively.
| Div yield(5 year avg) | 0.71% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 73.04% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -7.90 |
More ▼
